Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 10/20 | 0.53 |
| ▸ | WNT3A | P56704 | 10/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395494 | 0.81 | MAPT (0.56) | GAALMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL30089582 | 0.80 | CTNNB1 (0.75) | CTNNB1WNT3AGAALMNACNR2 | |
| SCHEMBL22659117 | 0.79 | CYP2C19 (0.43) | GAALMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2073272 | 0.78 | CTNNB1 (0.58) | CTNNB1WNT3AGAALMNACNR2 | |
| SCHEMBL19858887 | 0.78 | CTNNB1 (0.58) | CTNNB1WNT3AGAALMNACNR2 | |
| SCHEMBL1950901 | 0.77 | CTNNB1 (0.57) | CTNNB1WNT3AGAALMNACNR2 | |
| SCHEMBL8232789 | 0.77 | CTNNB1 (0.57) | CTNNB1WNT3AGAALMNACNR2 | |
| SCHEMBL5367757 | 0.77 | CTNNB1 (0.57) | CTNNB1WNT3AGAALMNACNR2 | |
| SCHEMBL2092338 | 0.77 | CTNNB1 (0.57) | CTNNB1WNT3AGAALMNACNR2 | |
| SCHEMBL5358195 | 0.77 | CTNNB1 (0.57) | CTNNB1WNT3AGAALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240277683-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-08-22 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-11766443-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-26 | — | — | US | disclosed |
| US-11766443-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-26 | — | — | US | disclosed |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| US-20220160725-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2022-05-26 | — | — | US | disclosed |
| WO-2008087529-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH S.P.A. (IT) | 2008-07-24 | — | — | WO | disclosed |
| EP-1937663-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | Inpharmatica Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007036730-A9 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LTD (GB) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008062026-A1 | 5-SULFANYLMETHYL-PYRAZOLO [1,5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007036730-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| US-20070010402-A1 | Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof | NIHON NOHYAKU CO., LTD., (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010402-A1 | Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof | NIHON NOHYAKU CO., LTD., (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010402-A1 | Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof | NIHON NOHYAKU CO., LTD., (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1544202-A1 | NOVEL HERBICIDES, USAGE THEREOF, NOVEL THIENOPYRIMIDINE DERIVATIVES, INTERMEDIATES OF THE SAME, AND PROCESS FOR PRODUCTION THEREOF | Nihon Nohyaku Co., Ltd. (JP) | 2005-06-22 | — | — | EP | disclosed |
| US-5034410-A | Nitrile and oxo containing amides or thioamides | SYNTEX (U.S.A.) INC. (US) | 1991-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160725-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | PTAFR, PDGFRA, F3 | CTNNB1 4386/4885WNT3A 4213/4885GAA 4686/4885 |
| US-20240277683-A1 | COMPOUNDS | SLC10A1, ABCB11, REN | CTNNB1 3254/4885WNT3A 2988/4885GAA 123/4885 |
| US-20070010402-A1 | Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof | DDT, DPYD, DHODH | CTNNB1 3560/4885WNT3A 3909/4885GAA 983/4885 |
| US-11766443-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | PTAFR, PDGFRA, F3 | CTNNB1 4386/4885WNT3A 4213/4885GAA 4686/4885 |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | AHR, ARNT, HMOX1 | CTNNB1 1296/4885WNT3A 1175/4885GAA 2109/4885 |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | PTAFR, PDGFRA, F3 | CTNNB1 4386/4885WNT3A 4213/4885GAA 4686/4885 |
| US-11911372-B2 | Compounds | SLC10A1, ABCB11, REN | CTNNB1 3113/4885WNT3A 2492/4885GAA 222/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | CTNNB1 1296/4885WNT3A 1175/4885GAA 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.